Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

NMRA - Neumora Therapeutics, Inc. Последние... | Finranks

Home

NMRA

(NMRA)

NMS – Цена в реальном времени. Валюта: USD

2.33

-0.16 (-6.43%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

2.36

+0.03 (1.22%)

После закрытия: Mar 27, 2026, 7:10 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that it will host a conference call and live webcast at 8:00 a.m. ET on Monday, March 30, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update.

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment

NMRA-511 demonstrated a clinically meaningful effect size in people with AD agitation.

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m.

Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript

Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript

Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced key pipeline updates and anticipated 2026 milestones that support the Company's mission to redefine neuroscience drug development with the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases.

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer's disease (AD) agitation.

Видео

No Data

There is no data to display

Пресс-релизы

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $NMRA--NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m.

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026 Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027 WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced key pipeline updates and anticipated 2026 milestones that support the Company's mission to redefine neuroscience drug development with the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases.

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation

NMRA-511 demonstrated a 15.7 reduction on mean CMAI total score, representing a clinically meaningful effect NMRA-511 demonstrated unsurpassed clinical effect size on CMAI total score in a pre-specified population with elevated anxiety NMRA-511 demonstrated a favorable tolerability and safety profile Neumora plans to evaluate higher doses of NMRA-511 via initiation of a multiple ascending dose expansion cohort in 2026 Company to host conference call today at 8:00 am ET WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced positive results from its Phase 1b signal-seeking study of NMRA-511 in people with Alzheimer's disease (AD) agitation.